On Demand 2023 Friday AM General Sessions

This course includes the following sessions from Friday morning's program:

  • Are You Using These Diagnostic Tests to Maximal Efficacy?
  • The Environment and the Allergist - Pollen and Practice Changes in the New Environment
  • The Evolution of Immunodeficiency Due to Medications and Malignancy
  • EAACI - New Responses to the Theoretical and Practical Challenge of Allergic Diseases


The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 6.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Target Audience

Medical professionals who treat patients with allergic and/or immunological conditions:

  • Practicing allergist/immunologists
  • Allergy/immunology Fellows-in-Training
  • Physician assistants
  • Nurses and advanced practice nurses
  • Allied health professionals
  • Primary care physicians
  • Other medical professionals

Learning Objectives

Upon completion of this session, participants should be able to:

  • Detail the impact of climate change on aeroallergens, pollen, and mold counts.
  • Consider potential disparities in care observed in their asthmatic and allergic patients from underserved populations related to the effects of climate change.
  • Identify the measures that can be used to implement an environmentally sustainable allergy practice.
  • Discuss the usefulness of available tests with their patients.
  • Demonstrate when to consider these tests in addition/in lieu of percutaneous tests.
  • Analyze how this compares to spirometry/plethysmography and make an informed decision on the use of spirometry testing.
  • Assess diagnostic and management strategies in SID patients due to B cell depletion.
  • Determine diagnostic and management strategies in SID patients due to systemic steroids.
  • Apply diagnostic and management strategies in SID patients due to emerging therapies.
  • Summarize and analyze new approaches to SID management.
  • Identify a novel approach to a new nomenclature of allergic diseases adapted to modern needs.
  • Analyze real world use of newly introduced biologics.
  • Cite changes to the EAACI Guidelines for Drug Allergy.
Additional information

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines a “ineligible company” as companies whose primary business is producing, marketing, selling, re-selling, or distributing health care goods or services, used by or on patients. Examples of such organizations include: 
•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers
The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.
Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.
Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified relevant financial relationships have been mitigated.

Course summary
Available credit: 
  • 6.25 AMA PRA Category 1 Credit™
  • 6.25 Attendance
  • 6.25 CBRN
Course opens: 
Course expires: 

Dan A. Dalan, MD, FACAAI
Mark C. Stahl, DO, FACAAI
Jeffrey G. Demain, MD, FACAAI
Bridgette L. Jones, MD
Todd L Sack, MD 
Bradley A. Locke, DO
Jonathan S. Tam, MD, FACAA
Jonathan Corren, MD, FACAAI
Julie Wang, MD, FACAAI
Stanley Galant, MD, FACAAI
Minto Porter, MD, FACAAI
Antoine E. Azar, MD
S. Shahzad Mustafa, MD, FACAAI
Heather K. Lehman, MD
Jolan Walter, MD
Marek Jutel, PhD
Stefano Del Giacco, MD, PhD
Maria Torres, MD, PhD

Available Credit

  • 6.25 AMA PRA Category 1 Credit™
  • 6.25 Attendance
  • 6.25 CBRN
Please login or create an account to take this course.